Semaglutide for the treatment of obesity
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.095Keywords
semaglutide, GLP-1 analogue, overweightAbstract
Introduction and purpose
Due to the growing tendency to diagnose obesity in patients, scientists are trying to find drugs that facilitate weight reduction.
An example of such a formulation is the GLP-1 analogue semaglutide. The following article is an analysis of the current knowledge on the effectiveness and safety of obesity treatment with semaglutide based on available publications in Pubmed and Google Scholar databases.
State of knowledge
The main mechanism of semaglutide is based on a stimulation of insulin secretion from pancreatic beta cells, and inhibition of glucagon from alpha cells, inhibition of hepatic gluconeogenesis, and reduction of energy consumption with minimal impact on energy expenditure. In clinical trials, it showed the best results compared to placebo and other drugs used in weight reduction. Participants treated with semaglutide achieved a reduction in waist circumference, improvements in blood pressure parameters, HbA1c levels, total cholesterol, LDL cholesterol, triglycerides, and CRP protein, and increased HDL cholesterol levels. Semaglutide is well tolerated by patients, and its main side effects come from the gastrointestinal tract, including nausea, emesis, diarrhea.
Summary
The analysis of the latest publications and meta-analyzes of the literature shows that the use of semaglutide is safe and effective in the treatment of obesity. The positive effect of semaglutide on weight reduction also contributes to the reduction of the risk of cardiovascular events and other obesity-related complications. It is also well tolerated by patients, which translates into possible longer use, and weekly subcutaneous injections are not burdensome for patients.
Key words: semaglutide; obesity; GLP-1 analogue; overweight
References
WHO. Obesity and overweight. 2021, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (dostęp: 21.08.22)
Ng M, Fleming T, Robinson M, et al.: Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014;384(9945):766-81.
Dietz W, Santos-Burgoa C.: Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring), 2020;28(6):1005
Aaseth J, Ellefsen S, Alehagen U, et al.: Diets and drugs for weight loss and health in obesity - An update. Biomed Pharmacother,2021;140:111789.
Ard J, Fitch A, Fruh S, et al.: Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther, 2021;38(6):2821–39.
U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. First Since 2014. 2021, https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (dostęp 21.08.22)
Smits MM, Van Raalte DH.: Safety of Semaglutide. Front Endocrinol (Lausanne), 2021;12:645563.
Arastu N, Cummins O, Uribe W, et al.: Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. Int J Clin Pharm, 2022.
Christou GA, Katsiki N, Blundell J, et al.: Semaglutide as a promising antiobesity drug. Obes Rev, 2019;20(6):805-815.
Lau J, Bloch P, Schäffer L, et al.: Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem, 2015;58(18):7370-7380.
Knudsen LB, Lau J.: The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne), 2019;10:155.
O'Neil PM, Birkenfeld AL, McGowan B, et al.: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 2018;392(10148):637-649.
Lingvay I, Desouza CV, Lalic KS, et al.: A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. Diabetes Care,2018;41(9):1926-1937.
Wilding JPH, Batterham RL, Calanna S, et al.: STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med,2021;384(11):989-1002.
Tan X, Cao X, Zhou M, et al.: Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs, 2017 ;26(9):1083-1089.
Shomali M.:Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. Clin Diabetes, 2014 ;32(1):32-43.
Ellero C, Han J, Bhavsar S, et al.: Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. Diabet Med, 2010;27(10):1168-73.
Nreu B, Dicembrini I, Tinti F, et al.: Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract, 2020;161:108087.
Seufert, J., et al.: P2857 Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial. European Heart Journal 39.suppl_1, 2018; ehy565-P2857.
Singh G, Krauthamer M, Bjalme-Evans M.: Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med, 2022 ;70(1):5-13.
Waldrop G, Zhong J, et al.: Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. J Diabetes Complications. 2018 Jan;32(1):113-122. doi: 10.1016/j.jdiacomp.2016.08.018.
Garvey WT, Mechanick JI, Brett EM, et al.: American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract, 2016;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL.
Bersoux S, Byun TH, Chaliki SS, Poole KG. Pharmacotherapy for obesity: What you need to know. Cleve Clin J Med, 2017;84(12):951-958. doi: 10.3949/ccjm.84a.16094.
Friedrichsen M, Breitschaft A, Tadayon S, et al.: The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab, 2021;23(3):754-762. doi: 10.1111/dom.14280.
Wilding JPH, Batterham RL, Calanna S, et al.: Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2021; 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med, 2021; S1050-1738(21)00158-4. doi: 10.1016/j.tcm.2021.12.008.
Davies M, Færch L, Jeppesen OK, et al.: Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 2021 ;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0.
Wadden TA, Bailey TS, Billings LK, et al.: Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 2021;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
Lazzaroni E, Ben Nasr M, Loretelli C, et al.: Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res, 2021;171:105782. doi: 10.1016/j.phrs.2021.105782.
Husain M, Birkenfeld AL, Donsmark M, et al.: PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med,2019;381(9):841-851.
Lee M, Lauren BN, Zhan T, et al.: The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract, 2019;6(2):162-170.
Blundell J, Finlayson G, Axelsen M, et al.: Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab, 2017;19(9):1242-1251. doi: 10.1111/dom.12932
Goldenberg RM, Steen O. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. Can J Diabetes, 2019 ;43(2):136-145. doi: 10.1016/j.jcjd.2018.05.008.
Capehorn MS, Catarig AM, Furberg JK, et al.: Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab, 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117.
Zinman B, Aroda VR, Buse JB, et al.: PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care,2019 ;42(12):2262-2271.
Thethi TK, Pratley R, Meier JJ.: Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab,2020 ;22(8):1263-1277.
Mizgier M, Jarząbek-Bielecka G, Jakubek E, Jeszka J. Zachowania zdrowotne dziewcząt w wieku prokreacyjnym a profilaktyka otyłości, zaburzeń płodności i powikłań położniczych – doniesienie wstępne. Piel Pol, 2016;4(62):524–528. DOI: http://dx.doi.org/10.20883/pielpol.2016.53
WHO. Overweight and obesity. 2018. http://www.who.int/gho/ncd/risk_factors/overweight/en/ (dostęp: 21.08.22)
WHO. Prevalence of obesity among adults, BMI ≥ 30, crude Estimates by WHO region. 2018. http://apps. who.int/gho/data/view.main.BMI30CREGv?lang=en (dostęp: 21.08.22)
Jaacks LM, Vandevijvere S, Pan A, et al.: The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol, 2019; 7: 231-240.
Narodowy Fundusz Zdrowia. Prezentacja raportu „Cukier, otyłość – konsekwencje”. 2019. https://www.nfz.gov.pl/aktualnosci/aktualnosci-centrali/prezentacja-raportu-cukier-otylosc-konsekwencje,7296.html (dostęp 21.08.22)
Krzysztoszek J, Wierzejska E, Zielińska A. Obesity. An analysis of epidemiological and prognostic research. Arch Med Sci, 2015 ;11(1):24-33. doi: 10.5114/aoms.2013.37343.
Honigberg MC, Chang LS, McGuire DK, et al.: Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiol,2020;5(10):1182-1190.
Oficjalny profil Ministerstwa Zdrowia na Twitterze.
https://twitter.com/MZ_GOV_PL/status/1560303201831817222?ref_src=twsrc%5Etfw (dostęp 21.08.22)
Charakterystyka produktu leczniczego Ozempic. https://leki.urpl.gov.pl/files/49_Ozempic.pdf (dostęp 21.08.22)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Rafał Oleszczuk, Iga Kozińska, Jordi Gras-Ozimek, Urszula Kozińska, Anna Oleszczuk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 33571
Number of citations: 0
